Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Name: Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Published: 2015
License: Public Domain

Merck Sharp & Dohme LLC · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

gastric-cancer

gastric adenocarcinoma, gastric carcinoma, gastric cancer, gastroesophageal junction cancer, gastroesophageal junction carcinoma, programmed cell death-1 (pd1, pd-1),, programmed death-ligand 1 (pdl1, pd-l1), programmed cell death receptor ligand 2 (pdl2, pd-l2), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Related documents